文献速递白血病

奥鲁替尼(FT-2102)在复发或难治性IDH1突变急性髓系白血病患者中诱导持久完全缓解

Olutasidenib (FT-2102) induces durable complete remissions in patients with relapsed or refractory IDH1-mutated AML.
PubMed 文献 · Blood Adv · 2023-01-01

这项关键队列研究纳入153例未接受过IDH1抑制剂的mIDH1R132复发/难治性急性髓系白血病患者,接受奥鲁替尼150 mg每日两次单药治疗。完全缓解加部分血液学恢复的完全缓解率为35%,总缓解率48%,中位完全缓解/部分血液学恢复的完全缓解持续时间25.9个月,中位总生存11.6个月。

要点

  • 奥鲁替尼单药在mIDH1R132复发/难治性急性髓系白血病中完全缓解加部分血液学恢复的完全缓解率为35%,总缓解率48%。
  • 中位完全缓解/部分血液学恢复的完全缓解持续时间25.9个月,中位总缓解持续时间11.7个月,中位总生存11.6个月。
  • 基线输血依赖的86例患者中29例(34%)达到56天输血不依赖;3级及以上治疗中出现的不良事件包括发热性中性粒细胞减少和贫血(各20%)等。

核心结论

  • 奥鲁替尼诱导持久缓解和输血不依赖,副作用谱明确且可控,在这一分子定义、预后不良的mIDH1复发/难治性急性髓系白血病人群中代表治疗进步。

研究设计与样本

  • 研究为关键队列,纳入153例未接受过IDH1抑制剂的mIDH1R132复发/难治性急性髓系白血病患者,接受奥鲁替尼150 mg每日两次单药治疗。
  • 患者中位年龄71岁(范围32-87岁),中位既往治疗方案数2(范围1-7)。
  • 试验注册于www.clinicaltrials.gov,编号#NCT02719574。

主要发现

  • 完全缓解加部分血液学恢复的完全缓解率为35%,总缓解率为48%。
  • 既往接受和未接受维奈克拉的患者缓解率相似。
  • 数据截止时55%患者删失,中位完全缓解/部分血液学恢复的完全缓解持续时间25.9个月。
  • 中位总缓解持续时间11.7个月,中位总生存11.6个月。
  • 基线输血依赖的86例患者中29例(34%)达到56天输血不依赖,包括所有缓解组患者。

关键数值与推荐

  • 3级或4级治疗中出现的不良事件(≥10%)包括发热性中性粒细胞减少和贫血(n=31;各20%)、血小板减少(n=25;16%)、中性粒细胞减少(n=20;13%)。
  • 特别关注的分化综合征不良事件发生于22例(14%)患者,其中14例(9%)为3级及以上,报告1例致死性病例。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Olutasidenib (FT-2102) is a potent, selective, oral, small-molecule inhibitor of mutant isocitrate dehydrogenase 1 (mIDH1). Overall, 153 IDH1 inhibitor-naive patients with mIDH1R132 relapsed/refractory (R/R) acute myeloid leukemia (AML) received olutasidenib monotherapy 150 mg twice daily in the pivotal cohort of this study. The median age of participants was 71 years (range, 32-87 years) and the median number of prior regimens received by patients was 2 (1-7). The rate of complete remission (CR) plus CR with partial hematologic recovery (CRh) was 35%, and the overall response rate was 48%. Response rates were similar in patients who had, and who had not, received prior venetoclax. With 55% of patients censored at the time of data cut-off, the median duration of CR/CRh was 25.9 months. The median duration of overall response was 11.7 months, and the median overall survival was 11.6 months. Of 86 patients who were transfusion dependent at baseline, a 56-day transfusion independence was achieved in 29 (34%), which included patients in all response groups. Grade 3 or 4 treatment-emergent adverse events (≥10%) were febrile neutropenia and anemia (n = 31; 20% each), thrombocytopenia (n = 25; 16%), and neutropenia (n = 20; 13%). Differentiation syndrome adverse events of special interest occurred in 22 (14%) patients, with 14 (9%) grade ≥3 and 1 fatal case reported. Overall, olutasidenib induced durable remissions and transfusion independence with a well-characterized and manageable side effect profile. The observed efficacy represents a therapeutic advance in this molecularly defined, poor-prognostic population of patients with mIDH1 R/R AML. This trial was registered at www.clinicaltrials.gov as #NCT02719574.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. de Botton S, Fenaux P, Yee K, et al. Olutasidenib (FT-2102) induces durable complete remissions in patients with relapsed or refractory IDH1-mutated AML. Blood Adv. 2023. PMID: 36724515. doi:10.1182/bloodadvances.2022009411

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。